Abstract: Using moxifloxacin and terfenadine, which are known to induce benign and malignant QT interval prolongation, respectively, we analysed whether halothane-anaesthetized microminipigs are an appropriate model for assessing the risk of druginduced long QT syndrome. Moxifloxacin (0.03, 0.3 and 3 mg/kg) and terfenadine (0.03, 0.3 and 3 mg/kg) were intravenously infused over 10 min. with a pause of 20 min. to the halothane-anaesthetized microminipigs (n = 4 for each drug). Moxifloxacin decreased the heart rate, whereas it increased the blood pressure in a dose-related manner. It also prolonged the PR interval and QT/QTc in a dose-related manner without altering the QRS width. Terfenadine decreased the heart rate and blood pressure, whereas it prolonged the PR interval, QRS width and QT/QTc in a dose-related manner. Terfenadine significantly prolonged the beat-to-beat variability of QT interval reflecting its pro-arrhythmic potential, which was not observed with moxifloxacin. The peak plasma concentrations of moxifloxacin and terfenadine after doses of 3 mg/kg were 4.81 and 10.15 lg/mL, respectively, which were both 1.5 times less in microminipigs than those previously reported in dogs. These results indicate that halothaneanaesthetized microminipigs would be useful for detecting drug-induced cardiovascular responses as well as differentiating benign from malignant QT interval prolongation like dogs, although there may be some differences in pharmacokinetic profile between these animals.
Dogs and/or monkeys have been used as experimental animals for assessing in vivo effect of drug candidate substances on electrocardiogram particularly on the QT interval [1, 2] . Considering ethical issues about animal welfare in addition to regulatory acceptability and similar biological characteristics to human beings, pigs have been attracting attention as an alternative animal in cardiac safety assessment [3] . However, it is difficult to use not only regular-sized pigs but also miniature pigs for obtaining in vivo proof, because they weigh 50 and 120 kg at 6 months of age, respectively, and therefore require much larger doses of a test article than dogs [4] . To overcome such difficulty, extraordinarily small-sized miniature pigs, namely microminipigs, weighing approximately 7.0 kg at 6 months of age when they are mature, were developed by Fuji Micra Inc. (Shizuoka, Japan) [4, 5] . However, the background information is still limited for microminipigs on assessing the drug-induced long QT syndrome, which will be indispensable to apply this novel animal to the field of cardiac safety pharmacology [6] .
In this study, we used microminipigs to investigate the pharmacokinetic and cardiovascular profiles of moxifloxacin and terfenadine, which are known to induce 'benign' and 'malignant' QT interval prolongation, respectively [2, [7] [8] [9] [10] . A fluoroquinolone antibiotic moxifloxacin is known to induce mild QT interval prolongation and has been recommended as a positive control by regulatory authorities to evaluate the sensitivity and reliability of QT/QTc studies because of its absence of clinical data on the onset of torsade de pointes [1, [11] [12] [13] [14] . Meanwhile, an antihistamine, terfenadine, has been withdrawn from the market in 1997 because of its high risk of QT interval prolongation followed by the onset of torsade de pointes [15] . To clarify the potential of microminipig as a proarrhythmia model, we analysed a well-established pro-arrhythmic surrogate marker, beat-to-beat variability of repolarization before and after the administration of moxifloxacin and terfenadine [16] [17] [18] [19] [20] .
Materials and Methods
Experiments were conducted in eight male microminipigs weighing approximately 9 kg, which were obtained from Fuji Micra Inc. All experiments were approved by the Toho University Animal Care and User Committee (No. 14-51-275; No. 15-52-275) and performed in accordance with the Guidelines for the Care and Use of Laboratory Animals of Toho University.
Cardiovascular variables. The microminipigs of 8 AE 1 months were pre-anaesthetized with an intramuscular injection of ketamine (16 mg/ kg) and xylazine (1.6 mg/kg). A 24-G cannula was inserted into a superficial auricular vein for anaesthetic injection of 1 mg/kg of propofol. After intubation with a 6-mm cuffed endotracheal tube, 1.0% halothane vaporized with 100% oxygen was inhaled with a Author for correspondence: Atsushi Sugiyama, Department of Pharmacology, Faculty of Medicine, Toho University, 5-21-16, Omori-nishi, Ota-ku, Tokyo 143-8540, Japan (e-mail atsushi.sugiyama@med. tohou.ac.jp). # These authors Contributed equally to the work. volume-limited ventilator (SN-480-3; Shinano Manufacturing Co., Ltd., Tokyo, Japan). Tidal volume and respiratory rate were set at 10 mL/kg and 15 breaths/min., respectively. Heparin calcium in a dose of 100 IU/kg was intravenously administered to prevent blood clotting via the auricular vein.
The electrocardiogram was obtained from the A-B lead. A clinically available 4F-size catheter-sheath set (XEMEX ISA0740BBA; Zeon Medical Inc., Tokyo, Japan) was placed in the right femoral artery to measure the aortic pressure. The corrected QT interval (QTc) was calculated with Van de Water's formula: QTc = QT À 0.087 9 (RR À 1000) [21] . Poincar e plots with QT n versus QT n+1 were prepared using total of 30 consecutive beats of electrocardiogram at pre-drug control (C) and after the administration of the drugs, at which the peak QT interval prolongation was observed. Short-term variability was calculated by the following equation:
Experimental protocol. The aortic pressure and electrocardiogram were monitored with a polygraph system (RM-6000; Nihon Kohden Co., Ltd., Tokyo, Japan) and analysed using a real-time fully automatic data analysis system (Win VAS 3 for Windows ver. 1.1R24v; Physio-Tech, Tokyo, Japan). Three recordings of consecutive complexes were used to calculate the mean for the cardiovascular variables. The electrocardiogram and aortic pressure were recorded under sinus rhythm. All parameters described above were usually obtained within 10 sec. at each time-point. After the basal assessment, moxifloxacin in a low dose of 0.03 mg/ kg was intravenously infused over 10 min., and each variable was assessed at 5, 10, 15, 20 and 30 min. after the start of administration. Next, moxifloxacin in a medium dose of 0.3 mg/kg was additionally infused over 10 min., and each variable was observed in the same manner as the low dose. Finally, moxifloxacin in a high dose of 3 mg/kg was infused over 10 min., and each variable was observed at 5, 10, 15, 20, 30, 45 and 60 min. after the start of the infusion. Then, the effects of terfenadine in doses of 0.03, 0.3 and 3 mg/kg on the cardiovascular parameters were assessed in the same manner. The doses of moxifloxacin and terfenadine were determined on the basis of previous reports [7, 8] .
Plasma drug concentration. A volume of 2 mL of blood was drawn from the femoral artery to measure the plasma drug concentration at 10, 15 and 30 min. after the start of the infusion for each dose of the drugs. In addition, it was done at 60 min. for the high dose. The blood samples were centrifuged at 1500 9 g for 30 min. at 4°C to prepare their plasma, which were then stored at À80°C until the drug concentration was measured. The plasma concentrations of moxifloxacin and terfenadine were determined by an HPLC method with slight modification as previously described [22] . The lower limit of quantification was 0.01 lg/mL for moxifloxacin and 1 lg/mL for terfenadine.
Drugs. Moxifloxacin hydrochloride (Avelox â tablet; Bayer Yakuhin, Ltd., Osaka, Japan) was extracted into distilled water in a concentration of 3 mg/mL, and then diluted with saline to concentrations of 0.3 and 0.03 mg/mL. Terfenadine (Sigma-Aldrich Co., St. Louis, MO, USA) was dissolved with 1% lactic acid in concentrations of 0.03, 0.3 and 3 mg/mL. Other drugs used were ketamine (Ketalar â ; Daiichi Sankyo Co., Ltd., Tokyo, Japan), xylazine (Celactal â ; Bayer Healthcare Co., Tokyo, Japan), propofol (Fresenius Kabi Co., Ltd., Tokyo, Japan), halothane (Fluothane â ; Takeda Pharmaceutical Co., Ltd., Osaka, Japan) and heparin calcium (Caprocin â ; Sawai Pharmaceutical Co., Ltd., Osaka, Japan).
Statistical analysis. Data are presented as the mean AE S.E. The statistical significances within a parameter were evaluated with oneway, repeated-measures analysis of variance (ANOVA) followed by Contrasts as a post hoc test for mean values comparison or paired t-test, whereas those between the groups were analysed by unpaired t-test. A p value <0.05 was considered to be statistically significant.
Results
Representative traces showing the effects of moxifloxacin and terfenadine on the electrocardiogram and aortic pressure are depicted in fig. 1 . Time courses of changes in the heart rate, mean blood pressure, PR interval, QRS width, QT interval and QTc are summarized in fig. 2 . Those of plasma concentrations are depicted in table 1 (n = 4 for each drug). There was no significant difference in any of the pre-drug control values of these variables between moxifloxacin-and terfenadineadministered groups.
Pharmacokinetic and pharmacodynamic profiles of moxifloxacin in microminipigs. Concentration of moxifloxacin peaked at 10 min. after starting infusion of each dose, as shown in table 1. The pre-drug control values (C) of the heart rate, mean blood pressure, PR interval, QRS width, QT interval and QTc were 77 AE 7 bpm, 64 AE 6 mmHg, 129 AE 11 ms, 82 AE 2 ms, 410 AE 21 ms and 426 AE 15, respectively. Moxifloxacin in the low dose of 0.03 mg/kg significantly prolonged the PR interval at 20 min., whereas no significant change was detected in the other variables. Moxifloxacin in the medium dose of 0.3 mg/kg significantly decreased the heart rate for 20-30 min. and prolonged the PR interval at 20 min., whereas no significant changes were detected in the other variables. Moxifloxacin in the high dose of 3 mg/kg significantly decreased the heart rate for 5-60 min., increased the mean blood pressure for 5-45 min. and prolonged the PR interval for 5-60 min., QT interval for 5-60 min. and QTc for 15-45 min. after the start of drug administration, whereas no significant change was detected in the QRS width.
Pharmacokinetic
and pharmacodynamic profiles of terfenadine in microminipigs. The peak plasma concentration of terfenadine was observed at 10 min. after the start of the infusion of high dose as shown in table 1. The pre-drug control values (C) of the heart rate, mean blood pressure, PR interval, QRS width, QT interval and QTc were 78 AE 9 bpm, 65 AE 6 mmHg, 132 AE 7 ms, 77 AE 3 ms, 388 AE 16 ms and 405 AE 10, respectively. Terfenadine in the low dose of 0.03 mg/kg did not alter any of the variables. Terfenadine in the medium dose of 0.3 mg/kg significantly decreased the heart rate for 5-30 min. and prolonged the QT interval for 5-30 min. and QTc for 10-30 min. after the start of drug administration, whereas no significant changes were detected in the other variables. Terfenadine in the high dose of 3 mg/kg decreased the heart rate for 5-60 min. and mean blood pressure for 5-60 min. and prolonged the PR interval and QRS width for 10-60 min. and QT interval and QTc for 5-60 min. after dosing.
Effects of moxifloxacin and terfenadine on the short-term variability of repolarization. The short-term variability of pre-drug control values (C) for moxifloxacin and terfenadine was 0.5 AE 0.0 and 0.3 AE 0.0 ms, respectively. Peak prolongation of the QT interval was confirmed at 30 min. after the high dose of Fig. 2 . Time courses of changes in the heart rate (HR), mean blood pressure (MBP), PR interval (PR), QRS width (QRS), QT interval (QT) and corrected QT interval (QTc) after intravenous administration of 0.03, 0.3 and 3 mg/kg of moxifloxacin (left panels) and terfenadine (right panels). Data are presented as mean AE S.E. (n = 4). Closed symbols represent significant differences from each pre-drug control value (C) by p < 0.05. moxifloxacin and at 45 min. after the high dose of terfenadine, at which short-term variability was 0.5 AE 0.0 ms (p = 0.99) for moxifloxacin and 1.8 AE 0.0 ms (p < 0.05) for terfenadine.
Discussion
In the present study, we pharmacologically characterized microminipigs as an in vivo experimental animal model by assessing two typical QT-prolonging drugs: moxifloxacin and terfenadine. We found that the halothane-anaesthetized microminipigs exhibited similar drug-induced QT interval responses to those in healthy human subjects [11, 20] and halothane-anaesthetized dogs [7, 8] . In addition, we clarified that microminipigs are capable of differentiating the benign QT interval prolongation by moxifloxacin from the malignant one by terfenadine. Moreover, we confirmed that most of the other cardiovascular responses were directionally similar to those in human beings and dogs and that less overall test article was needed for microminipigs than for dogs due to the smaller body-weight of microminipigs. These observations support the use of microminipigs for cardiac safety pharmacological assessment.
Pharmacokinetic and pharmacodynamic profiles of moxifloxacin.
Moxifloxacin at a dose of 3 mg/kg over 10 min. showed the peak plasma concentration of 4.8 lg/mL in microminipigs. Meanwhile, in 14 coronary artery bypass graft surgery patients with an average weight of 78.4 AE 7.8 kg, intravenous infusion of 400 mg of moxifloxacin over 60 min., which was roughly estimated as 5.1 mg/kg, attained a maximum plasma concentration of 5.1 lg/mL [23] . The peak plasma concentration can be estimated to be 3.8 times higher in human beings than in microminipigs at the equivalent dose and infusion duration. On the other hand, in the halothane-anaesthetized dogs, moxifloxacin at a dose of 3 mg/kg over 10 min. provided a peak plasma concentration of 7.0 AE 0.4 lg/mL [7] , indicating that plasma concentration was 1.5 times higher in beagle dogs than in microminipigs at the same dose. As microminipigs are newly developed animals from miniature pigs, we assume that the pharmacokinetic property of miniature pigs may have been maintained in microminipigs. Thus, the difference in the peak plasma concentrations of moxifloxacin may be partly explained by its volume of distribution in miniature pigs, dogs and human beings at a steady state, which has been reported to be 3.8, 2.7 and 2.0 L/kg, respectively [24] .
Moxifloxacin increased the mean blood pressure by 11% but decreased the heart rate by 13%, whereas it prolonged the PR interval by 8% in microminipigs. The mechanism of vasopressor effect in microminipigs remains unknown, whereas in dogs and human beings, moxifloxacin-induced hypotension via histamine release has been reported [25, 26] . The negative chronotropic and dromotropic effects may be induced by reflex-mediated increase in vagal tone in addition to the direct Ca 2+ channel inhibition [27] . These negative chronotropic and dromotropic effects are in good accordance with those assessed in halothaneanaesthetized guinea pigs with an intravenous dose of 3 mg/kg over 10 min. with C max of 3.5 lg/mL, in which moxifloxacin decreased the heart rate by 14% and prolonged the PR interval by 5% [28] . Similar trends in the heart rate and PR interval were observed in the halothane-anaesthetized dogs, which did not achieve statistical significance [7] . Meanwhile, the negative chronotropic and dromotropic effects have not been reported in human beings [12] . The cardiohemodynamic results indicate that moxifloxacin-induced histamine release might not occur in microminipigs, whereas these electrophysiological ones suggest that microminipigs may be more sensitive animals for detecting the negative chronotropic and dromotropic effects of moxifloxacin than dogs. Moxifloxacin in the dose of 3 mg/kg increased the QTcV by 19 ms in microminipigs. In the previous QT/QTc studies in healthy subjects, oral administration of 400 mg of moxifloxacin increased QT corrected with Fridericia's formula (QTcF) by 14.3 ms [14] . Also in beagle dogs, 3 mg/kg intravenous administration of moxifloxacin increased the QT corrected with Bazett's formula (QTcB) by 8 ms [7] . Therefore, halothane-anaesthetized microminipigs might be 2.4 times more sensitive for detecting the drug-induced QT interval prolongation compared with dogs, although the correction methods used were different from each other [7, 11] .
Pharmacokinetic and pharmacodynamic profiles of terfenadine.
Terfenadine at a dose of 3 mg/kg provided mean peak plasma concentration of 10.2 lg/mL ranging from 2 to 27 lg/mL . The values below the lower limit of quantification are indicated as ND, which were 0.01 lg/mL for moxifloxacin and 1 lg/mL for terfenadine. The plasma concentrations of moxifloxacin and terfenadine were determined by a HPLC method.
(n = 4) in microminipigs. Meanwhile, in anaesthetized dogs, terfenadine after intravenous administration of 3 mg/kg over 10 min. attained the maximum mean plasma concentration of 15.4 lg/mL ranging from 10.5 to 20.3 lg/mL (n = 6) [8] . Thus, microminipigs may have more variability in pharmacokinetic profile than dogs for terfenadine which is known to be completely metabolized to the active form fexofenadine in the liver by the enzyme cytochrome P450 (CYP) 3A after oral dosing [29] [30] [31] . The maximum plasma concentration of terfenadine in microminipigs was 1.5 times lower than in dogs, which might be partly explained by 2 times higher activity of CYP3A in the liver of microminipigs than that of beagle dogs [32] . In clinical practice, similar pharmacokinetic variability has been confirmed after a single oral dosing of 120 mg of terfenadine in healthy subjects, which attained the mean peak plasma concentrations varying from 0.006 to 0.5 lg/mL [33, 34] . The high dose of terfenadine decreased the heart rate by 47% and blood pressure by 43%, possibly due to the direct inhibitory action on Ca 2+ channels [35] . In clinical practice, terfenadine hardly altered the heart rate and blood pressure at an oral dose of 120 mg/day [36] . On the other hand, the decreases in the heart rate by 38% and blood pressure by 39% were observed in beagle dogs by intravenous infusion of 3 mg/kg over 10 min. [8] , suggesting that halothane-anaesthetized microminipigs are more sensitive than beagle dogs at the same plasma drug concentration in detecting drug-induced cardiohemodynamic responses. Terfenadine remarkably prolonged the PR interval by 36% in microminipigs, confirming its blockade actions on Ca 2+ channels, as previously reported in in vitro and in vivo studies [8, 35] . In human beings, terfenadine hardly altered the PR interval at an oral dose of 120 mg/kg, also possibly due to the extremely low concentration of parent compound terfenadine after oral administration [33, 34] . Meanwhile, in dogs, terfenadine prolonged the PR interval by 59%, of which extent of change was approximately 1.6 times greater than that of microminipigs, suggesting that beagle dogs are as sensitive as microminipigs in detecting terfenadine-induced negative dromotropic effect if plasma drug concentrations are at the same level. Terfenadine remarkably prolonged the QRS width by 23%, confirming its Na + channel blockade action, as previously reported in in vitro and in vivo studies [8, 37] . However, significant changes were not observed in dogs, suggesting that microminipigs are more sensitive than beagle dogs in detecting terfenadine-induced intraventricular conduction delay.
Terfenadine at a dose of 3 mg/kg significantly prolonged QTcV by 61 ms in microminipigs, confirming its inhibitory action on K + channels, as previously reported in in vitro and in vivo studies [8, 38] . In a prospective, controlled, doubleblind trial, terfenadine 60 mg twice-daily prolonged QTc by 6 ms in 28 healthy subjects [20] . Also, QTcB prolongation by 38 ms was observed in halothane-anaesthetized beagle dogs after intravenous administration of 3 mg/kg over 10 min., of which extent of change was 1.6 times greater in microminipigs than in dogs [8] , suggesting that microminipigs are more sensitive than beagle dogs in detecting terfenadine-induced ventricular repolarization delay.
Potential for pro-arrhythmic predictability of moxifloxacin and terfenadine by microminipigs.
Moxifloxacin hardly altered the short-term variability of the QT interval, but terfenadine significantly increased it, which well reflected the extent of well-known pro-arrhythmic potential of these drugs, namely the former only induces benign QT interval prolongation but the latter may trigger lethal arrhythmias following QT interval prolongation. These results are in accordance with those described in previous studies with the chronic atrioventricular block dogs [9, 10] . Thus, microminipigs can be used as a sensitive and reliable non-rodent model for predicting pro-arrhythmic potential of new chemical entities.
Conclusions
The present study characterized microminipigs as an in vivo experimental model by assessing the cardiovascular effects of two typical QT-prolonging drugs, moxifloxacin and terfenadine, compared with those of previous studies in human beings and dogs [7, 8, 14, 20] . The peak plasma concentrations of moxifloxacin and terfenadine are 1.5 times lower in microminipigs than those reported in dogs possibly due to a larger volume of distribution at steady state and higher activity of CYP3A in the liver, respectively. The drug-induced cardiovascular responses are directionally similar to those reported in dogs except that moxifloxacin increased the blood pressure. Importantly, terfenadine significantly prolonged the short-term variability of repolarization, reflecting its pro-arrhythmic potential, which was not observed by moxifloxacin. This information may encourage the use of microminipigs as an alternative model for cardiac safety assessment.
